Syndax Pharmaceuticals INC Form 4 insider transactions

Syndax Pharmaceuticals CEO Michael A. Metzger reported a transaction involving the sale of 32,375 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Head of R&D and CMO Nicholas A.J. Botwood exercised options and sold 65,515 shares of Syndax Pharmaceuticals common stock.

Syndax Pharmaceuticals CEO Michael A. Metzger sold 17,159 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Syndax Pharmaceuticals' CFO, Keith A. Goldan, sold 3,410 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Syndax Pharmaceuticals CEO Michael A. Metzger reported significant equity awards, including restricted stock units and stock options, alongside a sale to cover tax obligations.

Syndax Pharmaceuticals' CFO, Keith A. Goldan, increased his direct beneficial ownership through ESPP purchases and significant RSU and stock option grants, while also selling shares for tax obligations.

Syndax Pharmaceuticals Director Jennifer Jarrett received an award of 24,000 Restricted Stock Units, set to vest one year from the grant date.

Syndax Pharmaceuticals Director Martin H. Huber Jr. received a grant of 24,000 Restricted Stock Units, increasing his beneficial ownership to 103,000 shares.

Syndax Pharmaceuticals' Head of R&D and CMO, Nicholas A.J. Botwood, received substantial equity awards including restricted stock units and stock options.

Syndax Pharmaceuticals Director Dennis Podlesak was granted 48,000 Restricted Stock Units, increasing his beneficial ownership to 239,763 shares.

Syndax Pharmaceuticals Director Aleksandra Rizo received an award of 24,000 Restricted Stock Units, vesting in one year.

Syndax Pharmaceuticals Director Keith Katkin received an award of 24,000 Restricted Stock Units, increasing his direct beneficial ownership to 124,000 shares.

Syndax Pharmaceuticals director Pierre Legault was granted 24,000 Restricted Stock Units, aligning his interests with shareholders.

Syndax Pharmaceuticals' Chief Financial Officer, Keith A. Goldan, reported gifting 1,224 shares of common stock on December 1, 2025, under a Rule 10b5-1 plan.

Syndax Pharmaceuticals CEO Michael A. Metzger exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

A Syndax Pharmaceuticals director executed pre-planned sales of common stock after exercising options, realizing significant gains.

Syndax Pharmaceuticals' Chief Financial Officer, Keith A. Goldan, will acquire 1,226 shares of common stock at $8.43 per share on July 31, 2025, through the company's Employee Stock Purchase Plan.

Syndax Pharmaceuticals' Chief Financial Officer, Keith A. Goldan, reported the sale of 1,296 shares of common stock on July 16, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Syndax Pharmaceuticals Inc. CEO Michael A. Metzger sold 7,534 shares of common stock at $9.285 per share to cover tax withholding obligations related to restricted stock unit vesting.

Keith A. Goldan, CFO of Syndax Pharmaceuticals, recently purchased 3,000 shares of the company's common stock.

Nicholas A.J. Botwood, Head of R&D and CMO of Syndax Pharmaceuticals, reports a transaction involving the acquisition and disposition of common stock on May 16, 2025.

Director Huber Martin H. Jr. of Syndax Pharmaceuticals Inc. purchased 5,000 shares of common stock at $8.99 per share on May 19, 2025, and now owns 79,000 shares.

Director Keith Katkin purchased 10,000 shares of Syndax Pharmaceuticals at $9.112 per share on May 19, 2025.

Michael A. Metzger, CEO of Syndax Pharmaceuticals, exercised stock options and sold 6,074 shares of common stock on March 14, 2025.

Syndax Pharmaceuticals CEO Michael Metzger reports the sale of 7,814 shares of common stock at an average price of $15.0453, while also exercising options to acquire the same number of shares.

Keith A. Goldan, CFO of Syndax Pharmaceuticals, sold 3,777 shares of common stock on February 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Michael A. Metzger, CEO of Syndax Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, sold 4,618 shares of common stock on February 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, acquired shares and stock options in the company on February 5, 2025.

Keith A. Goldan, CFO of Syndax Pharmaceuticals, reports acquisition of common stock and stock options.